Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Curocell logo — Fight against hopelessness

Curocell

Fight against hopelessness

Founded 2016 Korea South Korea South 26 employees Venture round Total: $80.00B Biopharma, Biotechnology

General Information

Company Name Curocell
Founded Year 2016
Location Korea South Korea South
Employees 26
Industries Biopharma, Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Curocell. To contact Curocell, visit curocellbtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Curocell compare?

A PDF of Curocell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Curocell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Curocell

Curocell, founded in 2016 and headquartered in South Korea, is a cutting-edge company in the biopharma and biotechnology sectors. The company's slogan, "Fight against hopelessness," underscores its mission to revolutionize cancer treatment through the development of innovative CAR-T therapies.

Curocell focuses on unleashing the body's immune system using broad-spectrum CAR-T technologies targeting both blood and solid cancers. The company's distinctive approach involves programmed T cell product candidates that incorporate T cell modifying technology, aiming to overcome immune suppression and deliver greater efficacy than traditional CAR-T therapies.

The company attracted a significant KRW36.00B Venture Round investment on 04 January 2022, with support from notable investors including DS Asset Management, Ryukyung PSG, JX Partners, Seoul Investment Partners, Quad Asset Management, Widwin Investment, Moonchase Asset Management, Stick Ventures, and SK Plasma. These investments signal strong confidence in Curocell's innovative approach and potential market impact.

Business keywords: Curocell, cell therapy, CAR-T therapies, cancer treatment, immunotherapy, blood cancers, solid cancers, programmed T cell, immunotherapy technology, immune system, T cell modifying technology, immune suppression, efficacy, oncology

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round KRW36.00B 9
DS Asset Management Ryukyung PSG JX Partners
DS Asset Management, Ryukyung PSG +7
04 Jan 2022
Series C KRW44.00B 1
IMM Investment
IMM Investment
10 Aug 2020
Venture Round Undisclosed 1
STIC Ventures
01 Oct 2018
Venture Round Undisclosed 1
Company K Partners
Company K Partners
01 Jan 2018

Curocell Alternatives & Competitors

View All Alternatives
Curocell vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Compare Curocell vs Prescient Therapeutics
Curocell vs
T Cell Nouveau
T Cell Nouveau Japan

Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at...

1 employees
Biopharma, Biotechnology
Compare Curocell vs T Cell Nouveau
Curocell vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Curocell

Fight against hopelessness
Curocell was founded in 2016.
Curocell is headquartered in Korea South.
Curocell operates in Biopharma and Biotechnology. Its work centres on Curocell, cell therapy, CAR-T therapies and cancer treatment.
Curocell has approximately 26 employees.
Curocell has completed 4 funding rounds, raising a total of $80.00B. The latest funding stage is Venture round.
Top alternatives and competitors to Curocell include Prescient Therapeutics, T Cell Nouveau, 3T Biosciences, Glycyx, Umoja Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Curocell and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Curocell, https://bouncewatch.com/company/curocell, updated 12 August 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout